Fulgent Genetics (NASDAQ: FLGT) director awarded 11,117 restricted stock units

Rhea-AI Filing Summary

GROVES REGINA E reported acquisition or exercise transactions in this Form 4 filing.

Fulgent Genetics director Regina E. Groves received a grant of 11,117 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost per share and increased her direct holdings to 28,099 shares after the transaction.

The restricted stock units vest over four years. One quarter of the shares vest 12 months after May 14, 2026, and the remaining three quarters vest in equal 1/16 portions at the end of every three-month period over the following 36 months, subject to her continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GROVES REGINA E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	11,117	$0.00	--

Holdings After Transaction: Common Stock — 28,099 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 11,117 shares Post-transaction holdings: 28,099 shares Grant price per share: $0.0000 per share +2 more

5 metrics

RSU grant size 11,117 shares Restricted stock unit award on common stock

Post-transaction holdings 28,099 shares Common stock beneficially owned after acquisition

Grant price per share $0.0000 per share Restricted stock unit award price

Initial vesting date reference May 14, 2026 1/4 of RSUs vest 12 months after this date

Vesting schedule length 4 years RSUs vest over 12 months plus 36 additional months

Key Terms

Restricted stock units, vesting, beneficially own, Form 4

4 terms

Restricted stock units financial

"Restricted stock units. The shares subject to the restricted stock units vest over a period of four years"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"1/4th of such shares vesting 12 months after May 14, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

beneficially own financial

"total_shares_following_transaction: 28099.0000"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GROVES REGINA E

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CALIFORNIA 91731

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		11,117(1)	A	$0	28,099	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date.

	/s/ Paul Kim as Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Fulgent Genetics (FLGT) director Regina Groves report on this Form 4?

Regina E. Groves reported receiving 11,117 shares of Fulgent Genetics common stock as a restricted stock unit award. The grant was made at no cash cost per share and increased her directly held stake to 28,099 shares following the transaction.

How do Regina Groves’s new restricted stock units in FLGT vest over time?

The restricted stock units vest over four years. One quarter vests 12 months after May 14, 2026, and the remaining three quarters vest in 1/16 increments at the end of each three-month period over the next 36 months, contingent on continued service.

How many Fulgent Genetics shares does Regina Groves hold after this award?

After the restricted stock unit grant of 11,117 shares, Regina E. Groves is reported to beneficially own 28,099 shares of Fulgent Genetics common stock directly. This figure reflects her holdings immediately following the reported acquisition transaction on the Form 4.

Was cash paid for the restricted stock units granted to Regina Groves at Fulgent Genetics?

No cash was paid per share for this award. The Form 4 shows the 11,117 restricted stock units were granted at a price of $0.0000 per share, indicating they were an equity compensation grant rather than an open-market purchase.

What conditions must Regina Groves meet for her FLGT restricted stock units to vest?

Vesting of the restricted stock units is conditioned on continued service with Fulgent Genetics. Shares vest 12 months after May 14, 2026 for one quarter, and then in equal quarterly installments over the next 36 months if she remains in service on each vesting date.